Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorbipiprant (CR6086) + Methotrexate in Early Rheumatoid Arthritis
NCT03163966Phase 2Completed
- Sponsor
- Rottapharm Biotech
- Start
- Oct 2017
- Primary completion
- Jan 2019
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vorbipiprant in rheumatoid arthritis (RA) (4 arms), sponsored by Rottapharm Biotech. Primary endpoint: American College of Rheumatology 20% improvement at 12 weeks. Started Oct 2017; status: completed.
02
Drugs
vorbipiprant
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03163966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03163966.